

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method for the use of ghrelin or an analogue thereof for the preparation of a medicament for one or more of treatment and/or prevention of loss of body weight and body fat and/or prophylaxis or treatment of cachexia, and/or stimulation of appetite and/or stimulation of food intake and/or stimulation of weight gain and/or increasing body fat mass in a gastrectomized individual, comprising administering a therapeutically effective amount of ghrelin or analogue thereof to said individual.

2. (currently amended) The use method according to claim 1, wherein the ghrelin or analogue thereof is a ghrelin-like compound or a pharmaceutically acceptable salt thereof wherein the ghrelin-like compound comprises a structure defined by formula I



$Z^1$  is an optionally present protecting group  
each  $X^1$  is independently selected from an amino acid,  
wherein said amino acid is selected from the group  
consisting of naturally occurring and synthetic amino acids,  
 $X^2$  is any amino acid selected from the group consisting of  
naturally occurring and synthetic occurring amino acids,  
said amino acid being modified with a bulky hydrophobic  
group, ~~preferably an acetyl group, or a fatty acid,~~  
each  $X^3$  is independently selected from an amino acid,  
wherein said amino acid is selected from the group  
consisting of naturally occurring and synthetic amino acids,  
wherein one or more of  $X^1$  and  $X^3$  optionally may be modified  
by a bulky hydrophobic group, ~~preferably an acetyl group, or a~~  
~~fatty acid,~~  $Z^2$  is an optionally present protecting group,  
 $m$  is an integer in the range of from 1-10, and/or  
 $n$  is 0 or an integer in the range of from 1-35.

3. (currently amended) Use The method according to any of  
the preceding claims 2, wherein  $m$  is an integer in the range  
of from 1-9, ~~such as of from 1-8, such as of from 1-7, such as~~  
~~of from 1-6, such as of from 1-5, such as of from 1-4, such as~~  
~~of from 1-3, such as of from 1-2, such as 2.~~

4. (currently amended) Use The method according to any of the preceding claims 2, wherein  $X^2$  is selected from the group consisting of modified Ser, modified Cys and modified Lys, such as wherein  $X^2$  is modified Ser.

5. (currently amended) Use The method according to any of the preceding claims 2, wherein the ghrelin-like compound is selected from a compound the group consisting of:

formula II  $Z^1 - \text{Gly} - (X^1)_{m-1} - (X^2) - (X^3)_n - Z^2$ ,

formula III  $Z^1 - \text{Gly} - \text{Ser} - (X^2) - (X^3)_n - Z^2$ , and

formula IV  $Z^1 - \text{Gly} - (X^2) - (X^3)_n - Z^2$ .

6. (currently amended) Use The method according to any of the preceding claims 2, wherein the ghrelin-like compound is having formula III.

7. (currently amended) Use The method according to any of the preceding claims 2, wherein  $(X^3)_n$  comprises a sequence selected from one or more of the sequences shown below the group consisting of:

In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln (SEQ ID NO: 22)

Phe Leu Ser Pro Glu His (SEQ ID NO: 23)

Phe Leu Ser Pro Glu (SEQ ID NO: 24)

Phe Leu Ser Pro (SEQ ID NO: 25)

Phe Leu Ser (SEQ ID NO: 26)

Phe Leu (SEQ ID NO: 27)

Phe (SEQ ID NO: 28)

8. (currently amended) Use The method according to any of the preceding claims 2, wherein n is an integer in the range of from 1-25, such as of from 1-24, such as from 1-15, such as of from 1-10, such as of from 10-25, such as of from 10-24, such as of from 15-25, such as of from 15-24,

9. (currently amended) Use The method according to any of the preceding claims 2, wherein  $(X^3)_n$  is selected from the group consisting of one or more of the sequences shown below:

; : In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg (SEQ ID NO: 4)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala Lys Leu Gln Pro (SEQ ID NO:5 )

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala Lys Leu Gln (SEQ ID NO: 6)

.

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala Lys Leu (SEQ ID NO: 7)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala Lys (SEQ ID NO: 8)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro Ala (SEQ ID NO: 9)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro Pro (SEQ ID NO: 10)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys Pro (SEQ ID NO: 11)

: In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys Lys (SEQ ID NO: 12)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
Lys (SEQ ID NO: 13)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser  
(SEQ ID NO: 14)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu  
(SEQ ID NO: 15)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys (SEQ  
ID NO: 16)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg (SEQ ID  
NO: 17)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln (SEQ ID NO:  
18)

Phe Leu Ser Pro Glu His Gln Arg Val Gln (SEQ ID NO: 19)

Phe Leu Ser Pro Glu His Gln Arg Val (SEQ ID NO: 20)

: In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg (SEQ ID NO: 21)

Phe Leu Ser Pro Glu His Gln (SEQ ID NO: 22)

Phe Leu Ser Pro Glu His (SEQ ID NO: 23)

Phe Leu Ser Pro Glu (SEQ ID NO: 24)

Phe Leu Ser Pro (SEQ ID NO: 25)

Phe Leu Ser (SEQ ID NO: 26)

Phe Leu (SEQ ID NO: 27)

Phe (SEQ ID NO: 28)

10. (currently amended) Use The method according to any ~~of the preceding claims 2, wherein the bulky hydrophobic acyl~~ group is selected from a C1-C35 acyl group, such as a C1-C20 acyl group, such as a C1-C15 acyl group, such as a C6-C15 acyl group, such as a C6-C12 acyl group, such as a C8-C12 acyl group.

11-13. (cancelled)

14. (currently amended) ~~Use~~ The method according to any of the preceding claims 2, wherein the ~~medicament~~ comprises a solution of the ghrelin-like compound or a salt thereof is provided in the form of a solution.

15. (currently amended) ~~Use~~ The method ~~Use~~ according to claim 14, wherein the solvent is saline.

16-17. (cancelled)

18. (currently amended) The ~~use~~ method according to any of the preceding claims 1, wherein said ghrelin or analogue thereof is administered in combination with another stomach derived factor.

19. (cancelled)

20. (currently amended) The ~~use~~ method according to any of the preceding claims 1, wherein said ghrelin or analogue thereof is administered in combination with another body weight and/or body fat inducing factor.

21. (cancelled)

22. (currently amended) The use method according to any of the preceding claims 1, wherein the medicament ghrelin or analogue thereof is provided in a form is suitable for oral, nasal, transdermal, pulmonal, or parenteral administration.

23-26. (cancelled)

27. (currently amended) The method Use according to claim 1, any claims 1-22 wherein the ghrelin or analogue thereof is provided in a form suitable for subcutaneous administration medicament is in a formulation for parenteral administration.

28. (currently amended) The use method according to any of the preceding claims 1, wherein the active compound ghrelin or analogue thereof is administered in a dose of from about 0.01 µg/kg body weight to 10 mg/kg body weight daily, preferably between 0.1 to 10 µg /kg body weight.

29. (cancelled)

30. (currently amended) Use The method according to any of the preceding claims claim 1, wherein the medicament

In re of: JANSSON7

ghrelin or analogue thereof is administered prior to or during  
a meal.

31-37. (cancelled)